CENAS, a novel amplification-free nanopore sequencing-based approach with low cost and easy setup, has great potential for further development as a point-of-care test to offer an immediate bedside diagnosis of APL patients with a PML::RARA fusion, including atypical fusions. This evidence concerns the gene PML and acute promyelocytic leukemia.